KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition

Sorafenib, a multikinase inhibitor, is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, resistance to this regimen is frequently observed in clinical practice, and the molecular basis of this resistance remains largely unknown. Herein, the antitumor activi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Hu, Bo, Cheng, Jian-Wen, Hu, Jin-Wu, Li, Hong, Ma, Xiao-Lu, Tang, Wei-Guo, Sun, Yun-Fan, Guo, Wei, Huang, Ao, Zhou, Kai-Qian, Gao, Ping-Ting, Cao, Ya, Qiu, Shuang-Jian, Zhou, Jian, Fan, Jia, Yang, Xin-Rong
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6692625/
https://ncbi.nlm.nih.gov/pubmed/31417635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.31448
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados